William Blair & Company
NTLA icon

William Blair & Company’s Intellia Therapeutics NTLA Stock Holding History

William Blair & Company’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$233K Buy
18,210
+50
+0.3% +$637 ﹤0.01% 1421
2025
Q4 		$163K Sell
18,160
-2,000
-10% -$27.5K ﹤0.01% 1502
2025
Q3 		$348K Buy
+20,160
New +$248K ﹤0.01% 1256
2024
Q2 		– Sell
-10,307
Closed -$284K – 1860
2024
Q1 		$284K Buy
10,307
+57
+0.6% +$1.58K ﹤0.01% 1276
2023
Q4 		$313K Buy
10,250
+1,000
+11% +$28.7K ﹤0.01% 1234
2023
Q3 		$292K Hold
9,250
– – ﹤0.01% 1245
2023
Q2 		$377K Buy
9,250
+2,000
+28% +$81.1K ﹤0.01% 1158
2023
Q1 		$270K Sell
7,250
-110
-1% -$4.31K ﹤0.01% 1283
2022
Q4 		$257K Sell
7,360
-3,178
-30% -$151K ﹤0.01% 1284
2022
Q3 		$590K Buy
10,538
+178
+2% +$11K ﹤0.01% 984
2022
Q2 		$536K Sell
10,360
-2
-0% -$102 ﹤0.01% 1041
2022
Q1 		$753K Buy
10,362
+1,100
+12% +$93.2K ﹤0.01% 1020
2021
Q4 		$1.09M Buy
9,262
+152
+2% +$19K ﹤0.01% 923
2021
Q3 		$1.22M Hold
9,110
– – ﹤0.01% 853
2021
Q2 		$1.48M Hold
9,110
– – 0.01% 805
2021
Q1 		$731K Buy
9,110
+1,000
+12% +$67.1K ﹤0.01% 1002
2020
Q4 		$441K Buy
+8,110
New +$295K ﹤0.01% 1118
2019
Q4 		– Sell
-19,730
Closed -$263K – 1779
2019
Q3 		$263K Hold
19,730
– – ﹤0.01% 1174
2019
Q2 		$323K Sell
19,730
-2,530
-11% -$39.8K ﹤0.01% 1130
2019
Q1 		$380K Buy
22,260
+200
+0.9% +$2.98K ﹤0.01% 1056
2018
Q4 		$301K Buy
22,060
+12,060
+121% +$224K ﹤0.01% 1081
2018
Q3 		$286K Sell
10,000
-6,000
-38% -$175K ﹤0.01% 1157
2018
Q2 		$438K Buy
+16,000
New +$388K ﹤0.01% 986

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

William Blair & Company's NTLA Position: Q1 2026 in Review

William Blair & Company increased its Intellia Therapeutics (NTLA) stake by 0.28% in Q1 2026, buying an estimated $637 and bringing the position to 18,210 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #1421.

William Blair & Company first reported a position in NTLA in Q2 2018 and has held it in 23 quarters since. The position peaked at $1.48M in Q2 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • William Blair & Company held 18,210 shares of Intellia Therapeutics worth $233K as of Q1 2026.
  • William Blair & Company bought 50 Intellia Therapeutics shares in Q1 2026, an estimated $637.
  • Intellia Therapeutics made up ﹤0.01% of William Blair & Company's portfolio in Q1 2026, its #1421 holding.
  • William Blair & Company first reported a position in Intellia Therapeutics in Q2 2018 and has held it in 23 quarters since.
  • William Blair & Company's Intellia Therapeutics position peaked at $1.48M in Q2 2021.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.